Last updated on April 24, 2014 at 14:25 EDT

Aeterna Zentaris Presented Poster on Oral Prostate Cancer Vaccine, AEZS-120, at International Urology Conference in Japan

October 2, 2012

Filing of Clinical Trial Application (CTA) in Prostate Cancer Expected
in Q4 2012

QUEBEC CITY, Oct. 2, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the “Company”) today announced that preclinical data
on its oral prostate cancer vaccine candidate, AEZS-120, were presented
over the weekend at the 32(nd) Congress of the Société Internationale d’Urologie, which is being held in Fukuoka, Japan. The presentation underlined the
feasibility of an oral therapeutic vaccination approach against
prostate cancer. Furthermore, safety pharmacology and toxicology data
suggest that the profile of AEZS-120 is similar to the approved carrier
strain and, therefore, pave the way for Phase 1 clinical testing.

Juergen Engel, PhD, President and CEO at Aeterna Zentaris, commented,
“Now that we have completed the preclinical development program for
AEZS-120, we look forward to filing a Clinical Trial Application in
Europe during this quarter, in order to initiate a Phase 1 clinical
trial in prostate cancer with this novel oral anticancer vaccine.”

Summary and Conclusions

The production, release, pharmacology, safety and toxicology program was
conducted in agreement with the regulatory authorities and successfully

        --  The proof of concept has been shown in a tumor-challenge mouse
            model using the anticipated clinical application schedule;
        --  Biosafety and biodistribution studies did not reveal a
            different safety profile compared to the carrier strain;
        --  Pharmacological and toxicological studies did not reveal
            differences to the approved carrier strain;
        --  In all, the non-clinical studies suggest that the safety and
            toxicological profile of AEZ-120 is similar to the approved
            carrier strain S. typhi Ty21a, which has already been safely
            applied in more than 250 million doses;
        --  GMP material for clinical use has been produced and released;
            and CTA filing for Phase 1 clinical study is planned in 4Q

The poster titled, “Preclinical Proof of Concept and Characterization of AEZS-120, a
Therapeutic Oral Prostate Cancer Vaccine Candidate Based on Live
Recombinant Attenuated Salmonella
“, J. Fensterle, B. Bergmann, P. Schmidt, M. Teifel, J. Engel, T. Rudel,
W. Goebel, and U. Rapp, can be viewed by clicking on the following link.

About AEZS-120

AEZS-120 is a live recombinant oral tumor vaccine candidate based on Salmonella typhi Ty21a as a carrier strain. Salmonella typhi Ty21a is an approved oral typhoid vaccine which has been safely applied
in more than 250 million doses. The principle of AEZS-120 is based on
the recombinant expression of prostate specific antigen fused to the B
subunit of cholera toxin and a secretion signal in the presence of the Escherichia coli type I hemolysin secretion system. The proprietary system allows the
secretion of the antigen, together with an immunological adjuvant which
has been demonstrated to be required for optimal induction of CD8
T-cell responses by recombinant Salmonella based bacterial vaccines. The proof-of-concept was demonstrated for the
mouse homologue of AEZS-120 in a mouse tumor-challenge model. In
general, by varying the antigen and/or the carrier, this proprietary
platform technology should be suitable for virtually any therapeutic or
prophylactic vaccine indication with a favorable cost of goods
expectation in large scale.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company’s pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company’s actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy data
from any of our Phase 3 trials may not coincide with the data analyses
from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors should
consult the Company’s quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company
does not undertake to update these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, unless required to do so by a governmental authority or
by applicable law.


Source: PR Newswire